TD Cowen lowered the firm’s price target on Surgery Partners (SGRY) to $28 from $32 and keeps a Buy rating on the shares. The firm updated its model following Q4 results which were generally inline with FY25 and guidance slightly below.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners: Strong Growth and Strategic Positioning Drive Buy Rating
- Surgery Partners: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Surgery Partners Delays Annual Report Filing
- Buy Rating for Surgery Partners: Strong Revenue Growth, Strategic Developments, and Market Opportunities
- Surgery Partners price target lowered to $35 from $40 at Benchmark
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue